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INTRODUCTION 
According to the agreement between the Commission of the 
European Communities (DG VIII) and IEMVT, the research 
programme on the improvement of the Rinderpest vaccine 
thermostability started in May 1987, for a three-year period. 
From the very beginning, two different approaches were 
chosen: 
1 ) the development of a thermostable "clone" of the 
classical Plowright's virus, even if some modifications had 
to be brought to the present production techniques; 
2) the construction of a recombinant virus using a 
Poxvirus as a carrier. 
This report deals only with the development of the 
thermostable clone, the second point being the subject of 
another report following the recommendations of the meeting 
held in August in O. I.E. 
The laboratory work has been carried out by Mlle Calvez 
and the animal tests by Dr. A Diallo with the collaboration 
of the staff of the Farcha laboratory in Chad (Dr. Idriss Al 
Farouk and Dr. Bidgé) 
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I/ MATERIALS AND METHODS. 
I-1) Development of a thermostable "clone" 
A vaccine batch (98 BK) was left at 45 °C and titrations 
carried out every week on Vero cells. The wells of the final 
dilution giving a clear CPE were used to produce a new batch 
on Vero cells (98 BK, 2 Vero) that was freeze-dried and inc-
ubated at 45 °c as before. The operation was repeated three 
times consecutively (see figure 1). In the case of the 3rd 
batch, the virus was recuperated after 60 days at 45°C . 
Cell culture : The whole work was done with Vero cells 
( Pasteur Insti tute, Paris) grown in disposable trays wi th 
2 % FCS-MEM. 
The batches were freeze-dried using the Weybridge medium 
(casein hydrolysate 2.5 %, saccharose 5 %, Na glutamate 1 % 
- pH 7. 2) as a diluent ( aa) and according to the following 
scheme in a 68-70 hours cycle: 
Starting temperature - 45°C for 14 hours, then - 30°C 
for 4 hours, - 25°C for 4 hours, - 20°C for 14 hours , - 5°C 
for 4 hours, 0°c for 4 hours, 5°C for 14 hours, + 20°C for 4 
hours and finally + 35°C for 6 hours. The freeze-dryer 
equipment cornes from FTS System Inc. (N . Y.- U.S . A). 
The vials were stoppered under vacuum and stored ei ther at 
- 20°c or+ 45°C. 
"Cloning" was carried out in 24-wells plates using 5 
dilutions ( 1/2, 1/5, 1/10, 1/100, 1/1000) and 4 wells per 
dilution . The cells were observed every day and the results 
noted on day 10 and 12. 
All the celJ. cultures were _ incubated at 37 °C in a 5 % co2 
atmosphere. 
The thermostability of the virus at 45°C was increased 
at each passage associated wi th a reduction of the time of 
apparition of the CPE: 
1st passage (98 BK) 
2nd passage (98 BK, 2 Vero) 
3rd passage (98 BK, 4 Vero) 
I-2) Titration tests 
Day+ 18 
Day+ 35 
Day+ 60 
CPE in 15 days 
CPE in 10 days 
CPE in 6 days 
Titrations were carried out to estimate the half-life of 
bath viruses in 96-wells plates using 1 in 10 dilutions and 5 
wells per dilution. 
Each time, the CPE was noted at day 10 and the plates 
were fixed with aceton and an indirect immunofluorescent test 
practiced using a RP-rabbit hyperimmune anti-serum and a 
fluorescein labelled anti-rabbit IgG serum. 
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Figure 1 Developfî!ent of a thermostable "clone" 
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For each batch and on eac h date , three tests were 
performed on differe nt Ve ro c e ll cultures and the me an t iter 
cal c ul a t e d . 
I - 3) Virus-neutralisation tests 
The constant virus-variable serum VN tests were perfo rme d on 
Vero c'31-ls in 96-wells plates. The titer of the virus bank 
was 10 TCID5n per ml. 75 ul of the virus dilution is 
added to 75 ur of se~m dilution, incubated 1 hour at 37° C 
and then 50 ul of a 10 cells per ml suspension are added . 
The results are read at 10 days . 
I-4) Efficacy tests on animals 
The tests were carried out in Chad (Laboratoire de 
Farcha) on 11 young zebu cattle (6 to 10 months old): 
Before vaccination 
9 were serologically negative, 
1 was positive 1/4, 
1 was positive 1/2. 
Among the 9 negative animals , 
- 2 (N° 123, 167) received 50 dosis each, 
- 4 (N ° 153, 174, 187, 194) received 1 dosis each , 
- 3 (N ° 128, 165, 181) served as in-contact controls but 
only 2 were challengea afterwards. 
The 2 positive animals (N° 114, 152) were also kept in cont-
act with the vaccinate d animals and were challenge d. 
For the challenge, three weeks after vaccination, the 
Saudi Arabia strain (2 BK, 7 Vero) was inoculated 
N° 167 , 153, 174 , 165, 114 , 152 received 102 TCID50 
N° 123, 194, 181 received 103 TCID50 
N° 128 was not challenged. 
After vaccination and after challenge, blood samples 
were taken to monitor 1 ) the viremia of the vaccine and 
virulent strains (using inoculation of lymphocytes on tissue 
culture and the cDNA probe), 2) the antibody response. 
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II/ RESULTS 
II-1) Production of four batches 
After the potential thermostable "clone" was obtained, a 
seed bank was produced ( 98 BK, 6 Vero). Three batches of 
vaccine were prepared from this bank (batch A, Band C - 98 
BK, 7 Vero),freeze-dried and stored at + 45°C with a batch of 
vaccine prepared with the classical virus (99 BK) . 
Another batch (Th.Vac) was also prepared using the same 
seed bank but from vials kept for 60 days at +45°C. 
II - 2) Degradation curves at 45°C 
The resul ts of the ti tration tests are presented in 
Table 1 and Figures 2, 3, 4, 5 and 6. 
It is clear that the difference between the classical 
strain and the thermostable one is very important although it 
is not possible with so few points to establish a regression 
line for each batch. 
With the available results, two comments are possible: 
1) The degradation process for the thermostable 
strain is comparable to that of the classical strain, i . e . a 
rapid initial decay in 7-14 days and a gradual decay that 
looks like a plateau for at least 60 days ( batch A and 
Th. Vac. ) . 
2) More ti trations will be necessary to establish 
the complete degradation curve of the vaccine on a longer 
period (4 months and even more). 
The first conclusion is that the population of the 
thermostable vaccine is not homogeneous and that the selec-
tion pressure will have to be maintained. 
The second conclusion is that the thermostable vaccine 
as long as it is used with a certain number of precautions 
presents a great advantage on the classical vaccine. 
The titer calculated at Day +14 (at 45°C) seems to remain the 
same for 1 to 1.5 month (Batch A and Th.Vac.) or to decrease 
very slowly (Batch B and C). More titration tests, over a 
longer period, will permit to establish the "k constant" or 
"slope" of the degradation curve. ' 
NOTA : Preliminary results presented in the a previous 
report (half-life of 45 days) were indicative results. The 
curve drawn at that time was established on a batch prepared 
before the seed bank was completed and with a different free-
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ze - drying proc edure. With the curr ent r esu l t s, it seems t hat 
we are facing a more c omplex situation . 
Due to the two- phases degradation curve, spea king o f 
half-life does not mean much . 
II-3) Animal trials and virulent challenge 
All the classical tests recommended in the norms pub-
lished by O. I . E for the R.P vaccine production were carried 
out to see if the selection of a thermostable vaccine had not 
modified the initial properties of the attenuated RBOK 
strain. 
Safety tests : The 2 animals (N° 123 and 167) inoculated 
wi th 50 dosis showed no sign of clinical disease nor any 
significant rise in temperature . 
Efficacy tests : The 4 animals (N° 153, 174, 187 and 
194) inoculated with 1 dosis were protected when inoculated 
with the virulent strain while the negative controls (N°165 
and 181) died of classical RP . 
Excretion o f the vaccine stra in: The 3 contr o l animals 
left in contact wi th the vaccinated ones remained serolog-
ically negative after 3 weeks. 
Multiplication of the virulent strain in vaccinated 
animals : All the inoculations of lymphocytes on cell cul-
tures were negati ve. The diagnostic tests, performed till 
now, using the cDNA probe were also negative while they were 
positive for the control ani mals. 
Antibody levels : A significant rise o f the antibodies 
in vaccinated animals was detected as soon as 9 days after 
vaccination : 
N° 123 (50 dosis) 
N° 153 (1 dosis) 
N° 194 (1 dosis) 
N° 187 (1 dosis) 
N° 174 (1 dosis) 
1/16 
1 / 64 
1 / 16 
1 / 64 
1 / 64 
It can be noted tha t the level of antibodies does not 
depe nd on the number of dosis inoculated and that there is no 
booster effect after the challenge inoculation . 
(See figures : temperature and antibodies) . 
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CONCLUSION AND FUTURE TRENDS 
The thermostable vaccine that was selected at 4 5° C and 
cloned by the final dilution method seems to be a g ood 
candidate for use in Africa : 
1) After an initial decay during the first 2 weeks, the 
titer remains constant for 1.5 month at least . 
2) The virus is effective and has kept all t he 
properties of the initial RBOK strain. 
However, more work is needed: 
on the genetic stabili ty of the product when 
cultivated several times on cell culture without any 
selection pressure A batch has been prepared after 3 
consecutive passages in Vero cells and freeze-dried . The 
curve at 45°C will be established. The same operation will be 
performed after 10 and 15 passages . 
- on the exact degradation curve at 45 °C and on a 
longer period (4 or 5 months) . More titration tests will be 
carried out so that regression procedure on the second phase 
of the degradati on process will be possible . 
In order to check the sui tabili ty of the vaccine in 
African conditions, vials of the seed bank could be sent to 
one or several National laboratories with recommendations for 
use and batches produced in local conditions. 
The main recommendation should be, for the African 
laboratories, to prepare their own seed bank with 2 passages 
only and to keep this seed bank at 45°c for 2 we eks before 
using it for the production of a batch. 
It is evident that the production technique will be 
more complicated than the current one but in exchange for 
more s evere constraints on the laboratory, the field work 
becomes easier . 
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TABLE 1 Results of the titration tests 
Days at BATCH A BATCH B BATCH C ThV BATCH99 
45°C 
Before lyo- ND 5.2 6.6 ND ND 
philisation ND 5,4 6.2 ND ND 
ND 5.5 6.4 ND ND 
D 0 4.5 4 . 8 4 . 9 3 . 9 4.0 
4.6 4.6 5.2 4.2 4 . 2 
5 . 2 5.2 5.4 4.5 4 . 0 
mean 4.76 4.87 5.16 4.2 4.1 
D+7 4.2 4.4 4 . 9 3.9 2 . 8 
4 . 2 4.2 4.2 4.2 2.8 
4.2 4 . 4 4.9 3.6 2.5 
mean 4.2 4 . 33 4.66 3.9 2.7 
D+14 3.6 3.8 4.5 3.6 0 
3 . 8 4 . 2 4.4 3.6 0 
3 . 5 3.9 4.2 3.5 0 
mean 3.6 3.96 4.36 3.56 
D+ 30 3.6 3 . 5 3.8 3.5 0 
3.8 4.2 4.2 3.6 0 
3.6 3 . 6 3.6 3.6 0 
mean 3 . 66 3.76 3 . 86 3.56 
D+45 3.8 3.5 3.6 3.6 
3 . 5 3 . 6 3 . 5 3.4 
3.5 3 . 6 3.6 3.6 
mean 3.6 3.58 3.58 3.5 
D+60 3.6 3.3 3.5 
3.6 3.5 3.5 
3.5 3.3 3.4 
mean 3.56 3.41 3.46 
TABLE 2 
Batch A 
Batch B* : 
Batch B : 
Batch C* : 
Batch C 
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Residual moisture of the different batches 
on 20 vials per batch . 
mean = 0.99% (extremes = 0.8% and 1 . 5%) 
mean = 1.18% (extremes = 0.87% and 1.35%) 
mean = 1.17% (extremes = o. 9% and 1.6%) 
mean = 1.1 % (extremes = 0.66% and 1.43%) 
mean = 1.04% (extremes = 0.67% and 1.36%) 
Batch Th.Vac.: mean = 0.99% (extremes = 0.64% and 1.43%) 
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